Asia Deal Watch: Heartseed Licenses Lead Cell Therapy Candidate To Novo Nordisk
Executive Summary
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.